The California Institute for Regenerative Medicine (CIRM) has set goals in its five-year strategic plan to continue delivering the full potential of regenerative medicine to the people of California and around the world.
Public-private manufacturing partnerships
One goal is to overcome manufacturing hurdles in delivering regenerative medicine therapies by building a public-private manufacturing partnership network.
This is essential because the field needs standardized manufacturing processes to transition from producing smaller batches of therapies for clinical trials to the larger batches required for full-scale commercialization. Because cell and gene therapy manufacturing is more complex than other biologics, CIRM is committed to building a network to overcome these challenges.
To support that goal, CIRM is pleased to announce a new funding opportunity within our Infrastructure Program: the INFR5 Cell and Gene Therapy Manufacturing Network (Phase 1) Awards.
Goals of manufacturing network
The California Cell and Gene Therapy Manufacturing Network aims to establish a statewide manufacturing network comprising academic process development and GMP manufacturing facilities as well as industry manufacturing partners that will:
- Accelerate and de-risk pathways to commercialization for cell and gene therapies
- Advance industry standards and incorporate quality-by-design in cell and gene therapy manufacturing, and
- Build a diverse, highly skilled manufacturing workforce in California.
CIRM will issue two award phases under two separate requests for applications (RFAs). This RFA describes the first phase of awards that will fund California academic cell and gene therapy GMP manufacturing facilities to make initial progress toward the three network goals (described above) at their individual facilities.
Applications
To apply for this award, visit our website to download the Program Announcement and access the application link.
